Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncor gets additional export approvals:

This article was originally published in Clinica

Executive Summary

The US FDA has given Oncor (US) permission to export its investigational IVD genetic test systems for HER-2/neu and Chronic Myelogenous Leukaemia Mbcrlabl to Austria, Switzerland and Ireland. This follows export approvals granted earlier this year (see Clinica No 661, p 17). Oncor expects its HER-2/neu (ERBB2) gene amplification detection system for breast cancer to be reviewed by a US FDA panel in the final quarter this year. A PMA application was filed for the test in February 1994.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel